Genmab — April 2021
-
That I cannot - don’t know where to find it
-
Genmab wins our CEO performance ranking: Rescue plan turned into a success https://ugebrev.dk/ledelse/genmab-wins-our-ceo-performance-ranking-rescue-plan-turned-into-a-success/
-
Bulder - er det ikke 16.00?
-
Jeps, ET er 6 timer efter CET. Du får snart en ny chance Bulder;-)
-
As always E L find the news BEFORE they are published;-)
-
No not at all, very happy with the service you provide to Genmab investors here on PI D-)
-
-
Keep Going [email protected]....!!!
-
just had another link, but maybe this is best,
via https://meetinglibrary.asco.org/results/amivantamab;page=0?filters=JTVCJTdCJTIyZmllbGQlMjIlM0ElMjJZZWFyJTIyJTJDJTIydmFsdWUlMjIlM0ElMjIyMDIxJTIyJTJDJTIycXVlcnlWYWx1ZSUyMiUzQSUyMjIwMjElMjIlMkMlMjJjaGlsZHJlbiUyMiUzQSU1QiU1RCU3RCU1RA%3D%3D , ticked the year for 2021 -
2 for epcoritamab - Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity. and - Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind